# US 2001/0055629 A1 · Ginkgo biloba composition, method to prepare the same and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0055629 A1
- Document ID: US20010055629A1
- Status: Published application
- Kind: A1
- Application number: 09/768,678
- Filed: 2001-01-24
- Published: 2001-12-27
- Earliest claimed: 1998-03-19
- Assignees: Shanghai Xingling Sci. & Tech. Pharmaceutical Co., Ltd.
- Inventors: De Long Xie; Ning Wang; Qi Gao; Guo An Zhang; Bao Ping Shao; Xiao Wu Jin; Xin Sheng Huang
- Web page: https://patentgrep.com/patent/US20010055629A1

## CPC

- A61K 36/16: Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
- A61P 3/06: Antihyperlipidemics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- Y10S 435/967: Standards, controls, materials, e.g. validation studies, buffer systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

This invention provides different compositions extracted from Ginkgo biloba leaves. Said compositions comprise new active components. This invention also provides a method of preparation of the compositions and individual components of said compositions. Finally, this invention provides various uses of this composition.

## Claims

### Claim 1

A composition comprising:
(a) about 44% to about 78% flavonoids;
(b) about 2.5% to about 10% ginkgolides selected from ginkgolide A, B, C, J or a combination thereof:
(c) about 2.5% to about 10% bilobalide; and
(d) about 0.1 ppm to about 5 ppm of ginkgolic acids.

### Claim 2

A composition comprising:
(a) about 44% to about 78% flavonoids that include flavonols, flavanols and flavonol glycosides;
(b) about 2.5% to about 10% ginkgolides selected from ginkgolide A, B, C, J or a combination thereof:
(c) about 2.5% to about 10% bilobalide; and
(d) about 0.1 ppm to about 5 ppm of ginkgolic acids.

### Claim 3

A composition comprising:
(a) about 44% to about 78% flavonoids with a content of about 20% to about 75% flavonol glycosides;
(b) about 2.5% to about 10% ginkgolides selected from ginkgolide A, B, C, J or a combination thereof;
(c) about 2.5% to about 10% bilobalide; and
(d) about 0.1 ppm to about 5 ppm ginkgolic acids.

### Claim 4

A composition comprising:
(a) about 44% to about 78% flavonoids which comprises flavonol glycosides and flavonols, with a content ratio between flavonol glycosides and flavonols as 1-30:1;
(b) about 2.5% to about 10% ginkgolides selected from ginkgolide A, B, C, J or a combination thereof;
(c) about 2.5% to about 10% bilobalide; and
(d) about 0.1 ppm and 5 ppm ginkgolic acids.

### Claim 5

A composition comprising:
(a) about 44 to about 78% flavonoids comprising flavonol glycosides;
(b) about 5% to 20% of lactones, wherein the lactones comprising 2.5% to about 10% ginkgolides selected from ginkgolide A, B, C, J or mixtures thereof and about 2.5% to about 10% bilobalide;
(c) the ratio of flavonol glycosides to lactones is about 3.5-4.5:1; and
(d) about 0.1 ppm and 5 ppm ginkgolic acids.

### Claim 6

A composition comprising:
(a) not less than 44% flavonoids comprising flavonol glycosides;
(b) not less than 6% lactones comprising ginkgolides selected from ginkgolide A, B, C, J or a combination thereof and bilobalide; and
(c) about 0.1 ppm and 5 ppm ginkgolic acids.

### Claim 7 (depends on 1, 2, 3, 4, 5, 6)

The composition of claim 1, 2, 3, 4, 5 or 6 wherein the concentration of ginkgolic acids is about 0.1 ppm to about 0.5 ppm.

### Claim 8 (depends on 1, 2, 3, 4, 5, 6)

The composition of claim 1, 2, 3, 4, 5 or 6 wherein the composition having components extracted from Ginkgo biloba leaves.

### Claim 9 (depends on 7)

The composition of claim 7 wherein the composition having components extracted from Ginkgo biloba leaves.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6)

The composition of claim 1, 2, 3, 4, 5 or 6 wherein the Ginkgo biloba leaves are obtained from cultivated plants.

### Claim 11 (depends on 7)

The composition of claim 7 wherein the Ginkgo biloba leaves are obtained from cultivated plants.

### Claim 12

A method for obtaining a Ginkgo biloba composition comprising steps of:
(a) obtaining dried Ginkgo biloba leaves;
(b) breaking the leaves into small pieces;
(c) putting the broken leaves through a process of reflux in a solution selected from water, alkanols with C1 to C3, acetone, and a combination thereof under conditions permitting the extraction of flavonoids and lactones to produce an extract and a residue;
(d) separating the extract from the residue;
(e) concentrating the separated extract to a density of about 1.2 to about 1.25 at 60° C.;
(f) applying the concentrate from step (e) to at least two kinds of resin under conditions permitting binding of flavonoids and lactones;
(g) eluting the bound flavonoids and lactones, thereby producing an extract containing flavonoids and lactones from Ginkgo biloba.

### Claim 13 (depends on 12)

The method of claim 12, wherein in step (f), the resins are packed in columns.

### Claim 14 (depends on 12)

The method of claim 12, wherein the resin is porous polymer, silicon gel, Aluminum oxide, polyamide, activated charcoal, cellulose or sephedax.

### Claim 15 (depends on 13)

The method of claim 13, wherein the column is eluted with water, alkanols with C1 to C3, acetone, or ester which is methyl or ethyl ester.

### Claim 16

A method for identification and examination of the flavones in a Ginkgo biloba composition comprising steps of:
(a) preparing the assay by dissolving the composition in methanol;
(b) preparing the standard by putting standard Ginkgo biloba leaves and 60% aqueous alcohol through a process of reflux; after filtration, concentrate the filtrate to evaporate off alcohol; extract the concentrated aqueous solution with petroleum, ethyl acetate and n-butanol respectively; concentrate the n-butanol portion to dryness and dissolve it in methanol;
(c) performing the assay according to the TLC method by spotting each of the above-mentioned solution on the same thin silicon plate, developing the plate with a mixture of ethyl acetate, formic acid, acetic acid and water; then the plate is removed, air-dried, sprayed with 1% aluminum chloride in ethanol solution and observed under ultra-violet light at 365 nm; in both test and control chromatograms, eight yellow spots occur at the identical locations.

### Claim 17

A method for identification and examination of the terpene lactones in a Ginkgo biloba composition comprising steps of:
(a) preparing the assay by putting the composition and ethyl acetate through a process of reflux; after filtration, concentrate the filtrate to dryness and dissolve it in methanol;
(b) preparing the standard by dissolving each standard sample of ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and bilobalide in methanol to make five standard solutions;
(c) performing the assay according to the TLC method by pipetting each of the above-mentioned solutions on the same silica gel GF254 thin layer plate respectively, developing the plate with a mixture of ethyl acetate, toluene, acetone and cyclohexane; then the plate is removed, air-dried, heated and observed under 254 nm ultra-violet light; in both test and control chromatograms spots of the same color occur at the identical locations.

### Claim 18

A method for identification and examination of the ginkgolic acids in a Ginkgo biloba composition comprising steps of:
(a) preparing the assay by putting the composition and n-hexane through a process of reflux; after filtration, concentrate the filtrate to dryness and dissolve it in ethyl acetate;
(b) preparing the standard by adding ethyl acetate to standard compounds of ginkgolic acids;
(c) performing the assay according to the TLC method by pipetting each of the above mentioned solutions on the same thin-silicon-plate (GF254); then the plate is developed with a mixture of n-hexane, ethyl-acetate and acetic acid, removed, air-dried and observed under 315 nm and 368 nm ultra-violet; the absorbance of the sample should be less than that of the standard solution.

### Claim 19

A method for determination of the total amount of the flavonoids in a Ginkgo biloba composition comprising steps of:
(a) preparing the standard by dissolving dry rutin with 70% aqueous alcohol;
(b) obtaining the standard curve by pipetting different amount of the standard solution to a container; to each container add water, buffer (pH=4.5) of acetic acid, sodium acetate, 0.1 M aluminum chloride and 70% aqueous alcohol; plot the standard curve by obtaining the absorbance of each sample at 270 nm;
(c) performing the assay according to the spectrophotometric method by dissolving the composition with 70% aqueous alcohol; pipetting the solution into a container and prepare the sample solution by using the same met-hod described above; according to the standard curve, the concentration of the sample could be obtained by detecting its absorbance at 270 nm; the total content of flavonoids, calculated on the anhydrous basis, by rutin, is in the range of 85%-115% of the labeled amount.

### Claim 20

A method for determination of the amount of the flavonol glycosides in a Ginkgo biloba composition comprising steps of:
(a) preparing the assay by dissolving the composition with methanol and 25% hydrochloride and putting it through a process of reflux; then it is removed, left to cool and transferred to a container; the boiling container is washed with methanol and the washing solutions are decanted to the container, diluted to volume with methanol;
(b) preparing the standard by dissolving quercetin, kaempferol and isorhamnetin in the same container; that is then diluted with methanol;
(c) performing the assay by calculating the area of relative peaks on the HPLC spectrum in order to determine the amount of quercetin, kaempferol and isorhamnetin; the total amount of flavonol glycosides=amount of quercetin×2.50+amount of kaempferol×2.63+amount of isorhamnetin x 2.36.

### Claim 21

A method for determination of the amount of the terpene lactones in a Ginkgo biloba composition comprising steps of:
(a) preparing the assay by putting the composition and acetone through a process of reflux; after filtration, concentrate the filtrate and dissolve the residue in methyl acetate, followed by an extraction with water; the water layer is extracted with methyl acetate again; the two methyl acetate layers are combined, concentrated to dryness and dissolved in methanol;
(b) preparing the standard by dissolving each ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and bilobalide with methanol in the same container;
(c) performing the assay according to the HPLC test method by injecting SP and AP respectively to the column and their chromatogram are taken; the amount of ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and bilobalide is calculated by the method for external standard in individual monograph, then they are summed up to obtain the total amount of terpene lactones.

### Claim 22 (depends on 17)

The method of claim 17, wherein the monomers of ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and bilobalide are used as the standards to identify the terpene lactones in a Ginkgo biloba composition.

### Claim 23 (depends on 18)

The method of claim 18, wherein the monomers of Ginkgolic acids are used as the standards to identify the Ginkgolic acids in a Ginkgo biloba composition.

### Claim 24 (depends on 19)

The method of claim 19, wherein the monomer of rutin is used as the standard to determine the total amount of flavonoids in a Ginkgo biloba composition.

### Claim 25 (depends on 20)

The method of claim 20, wherein the monomers of quercetin, kaempferol, isorhamnetin are used as the standards to determine the amount of flavonols and flavonol glycosides in a Ginkgo biloba composition.

### Claim 26 (depends on 21)

The method of claim 21, wherein the monomers of ginkgolide A, ginkgolide B, ginkgolide C, ginkgolide J and bilobalide are used as the standards to determine the amount of the terpene lactones in a Ginkgo biloba composition.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6)

The composition of claim 1, 2, 3, 4, 5 or 6 used as food additive or added into beverages.

### Claim 28 (depends on 7)

The composition of claim 7 used as food additive or added into beverages.

### Claim 29 (depends on 1, 2, 3, 4, 5, 6)

The composition of claim 1, 2, 3, 4, 5 or 6 added into cream, ointment or added into the raw materials to prepare the same.

### Claim 30 (depends on 7)

The composition of claim 7 added into cream, ointment or added into the raw materials to prepare the same.

### Claim 31 (depends on 1, 2, 3, 4, 5, 6)

An oral formulation containing the composition of claim 1, 2, 3, 4, 5 or 6.

### Claim 32 (depends on 7)

An oral formulation containing the composition of claim 7.

### Claim 33 (depends on 31)

The oral formulation of claim 31, wherein the formulation is a pill, capsule, granule, tablet or a suspension.

### Claim 34 (depends on 32)

The oral formulation of claim 32, wherein the formulation is a pill, capsule, granule, tablet or a suspension.

### Claim 35 (depends on 1, 2, 3, 4, 5, 6)

An injectable formulation containing the composition of claim 1, 2, 3, 4, 5 or 6.

### Claim 36 (depends on 7)

An injectable formulation containing the composition of claim 7.

### Claim 37 (depends on 1, 2, 3, 4, 5, 6)

A cosmetic formulation containing the composition of claim 1, 2, 3, 4, 5 or 6.

### Claim 38 (depends on 7)

A cosmetic formulation containing the composition of claim 7.

### Claim 39 (depends on 1, 2, 3, 4, 5, 6)

A pharmaceutical composition comprising an effective amount of the composition of claim 1, 2, 3, 4, 5 or 6 and a pharmaceutically acceptable carrier.

### Claim 40 (depends on 7)

A pharmaceutical composition comprising an effective amount of the composition of claim 7 and a pharmaceutically acceptable carrier.

### Claim 41 (depends on 38)

A method for treating angina pectoris of various kinds and degrees induced by coronary heart disease in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 42 (depends on 39)

A method for treating angina pectoris of various kinds and degrees induced by coronary heart disease in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 43 (depends on 38)

A method for improving ischemic electrocardiogram in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 44 (depends on 39)

A method for improving ischemic electrocardiogram in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 45 (depends on 38)

A method for relieving angina pectoris in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 46 (depends on 39)

A method for relieving angina pectoris in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 47 (depends on 38)

A method for reducing the usage of nitroglycerin in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 48 (depends on 39)

A method for reducing the usage of nitroglycerin in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 49 (depends on 38)

A method for relieving palpitation in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 50 (depends on 39)

A method for relieving palpitation in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 51 (depends on 38)

A method for decreasing cholesterol and triglyceride level in blood for a subject with abnormal blood-lipid comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 52 (depends on 39)

A method for decreasing cholesterol and triglyceride level in blood for a subject with abnormal blood-lipid comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 53 (depends on 38)

A method for decreasing platelet aggregation in the blood of a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 54 (depends on 39)

A method for decreasing platelet aggregation in the blood of a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 55 (depends on 38)

A method for improving exercise tolerance and extending exercise duration, interval between exercise initiation and angina occurrence and interval between exercise initiation and 1 mm. decrease of ST segment in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 56 (depends on 39)

A method for improving exercise tolerance and extending exercise duration, interval between exercise initiation and angina occurrence and interval between exercise initiation and 1 mm. decrease of ST segment in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 57 (depends on 38)

A method for treating impotence in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 58 (depends on 39)

A method for treating impotence in a subject comprising administering to the subject. an effective amount of the pharmaceutical composition of claim 39.

### Claim 59 (depends on 38)

A method for treating psoriasis in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 60 (depends on 39)

A method for treating psoriasis in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 61 (depends on 38)

A method for treating pigment precipitation in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 62 (depends on 39)

A method for treating pigment precipitation in a subject comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.

### Claim 63 (depends on 38)

A method for treating absent-mindedness, AIDS, Alzheimer's disease, angina pectoris, arteriosclerosis, arthritis, asthma, atherosclerosis, autism, bed-wetting, brain trauma, cardiac disorders, chilblain, chills, coronary heart disease, deafness, dementia, depression, diabetic vasoconstriction with gangrene and angina, dizziness, eye disorders, failing memory, fatigue, filariasis, headache, hypercholesterolemia, hypertension, intermittent claudication, kidney disorders, leg cramps, myocardial infarction, Parkinson's disease, poor circulation, postthrombotic syndrome, Raynaud's syndrome, rheumatism, senility, thorax suffocation, tinnitus aurium, tuberculosis, varicose veins and vertigo comprising administering to the subject an effective amount of the pharmaceutical composition of claim 38.

### Claim 64 (depends on 39)

A method for treating absent-mindedness, AIDS, Alzheimer's disease, angina pectoris, arteriosclerosis, arthritis, asthma, atherosclerosis, autism, bed-wetting, brain trauma, cardiac disorders, chilblain, chills, coronary heart disease, deafness, dementia, depression, diabetic vasoconstriction with gangrene and angina, dizziness, eye disorders, failing memory, fatigue, filariasis, headache, hypercholesterolemia, hypertension, intermittent claudication, kidney disorders, leg cramps, myocardial infarction, Parkinson's disease, poor circulation, postthrombotic syndrome, Raynaud's syndrome, rheumatism, senility, thorax suffocation, tinnitus aurium, tuberculosis, varicose veins and vertigo comprising administering to the subject an effective amount of the pharmaceutical composition of claim 39.
